Matthew Gall

Chief Financial Officer, iTeos Therapeutics, Inc.

Companies

Tango Therapeutics (United States)Chief financial officer Apr 24, 2026 to now¹
iTeos Therapeutics, Inc.Chief financial officer Jul 23, 2020 to now²
Kalaris Therapeutics, Inc.Chief financial officer Nov 3, 2025 to Jul 20, 2026³

Stock this person has reported owning, from the forms officers and directors file with the SEC. See the biggest insider stakes.

Tango Therapeutics (United States) TNGX40,000 shares⁴$898.0K at $22.45May 1, 2026
iTeos Therapeutics, Inc.0 shares⁵Aug 29, 2025

As of each latest filing. The line shows shares held over time.

May 1, 2026Granted 40,000 shares of Tango Therapeutics (United States)⁴
Aug 29, 2025U 89,429 shares of iTeos Therapeutics, Inc.⁵
Mar 7, 2025Granted 24,000 shares of iTeos Therapeutics, Inc.⁶
Nov 19, 2024Bought 5,000 shares at $7.73 of iTeos Therapeutics, Inc.⁷
Dec 5, 2023Granted 41,000 shares of iTeos Therapeutics, Inc.⁸
Oct 12, 2023Bought 5,000 shares at $8.37 of iTeos Therapeutics, Inc.⁹
Dec 27, 2021Sold 5,000 shares at $46.45 of iTeos Therapeutics, Inc.¹⁰
Oct 11, 2021Exercised options 14,429 shares at $6.16 of iTeos Therapeutics, Inc.¹¹

The numbers on this page point here. Each one links to the record it came from.